# Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

> We show that SARS-CoV-2 mRNA vaccines lead to development of antibodies in immunosuppressed patients without considerable side effects or induction of disease flares. Despite the small size of this cohort, we were able to demonstrate the efficiency and safety of mRNA vaccines in our cohort....

## Metadata
- Authors: Ulf Geisen, Dennis K Berner, Florian Tran, Melike Sümbül, Lena Vullriede, Maria Ciripoi, Hayley M Reid, Annika Schaffarzyk, Ann Carolin Longardt, Jeanette Franzenburg, Paula Hoff, Jan Henrik Schirmer, Rainald Zeuner, Anette Friedrichs, Andrea Steinbach, Christine Knies, Robert Markewitz, Peter J. Morrison, Sascha Gerdes, Stefan Schreiber, Bimba F. Hoyer
- Journal: Annals of the Rheumatic Diseases
- Published: 2021-03-24
- DOI: https://doi.org/10.1136/annrheumdis-2021-220272
- Citations: 376
- Source: OpenAlex
- Access: Open Access

## Technology Hub
- Hub: mRNA Therapies
- Discipline: Medicine / Biotechnology
- Hub URL: https://science-database.com/technology/mrna-therapies
- Hub llms.txt: https://science-database.com/technology/mrna-therapies/llms.txt

## Abstract
We show that SARS-CoV-2 mRNA vaccines lead to development of antibodies in immunosuppressed patients without considerable side effects or induction of disease flares. Despite the small size of this cohort, we were able to demonstrate the efficiency and safety of mRNA vaccines in our cohort.

## Links
- DOI: https://doi.org/10.1136/annrheumdis-2021-220272
- OpenAlex: https://openalex.org/W3139490202
- PDF: https://ard.bmj.com/content/annrheumdis/80/10/1306.full.pdf
- JSON API: https://science-database.com/api/v1/technology/mrna-therapies

---
Generated by science-database.com — The Knowledge Interface
Paper ID: oa-W3139490202 | Hub: mrna-therapies